NCT01521065View on ClinicalTrials.gov

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

PHASE2UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2016

Conditions
Age-Related Macular DegenerationWet Macular DegenerationMacular DegenerationEye DiseasesRetinal Diseases
Interventions
DEVICE

IRay

Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.

Trial Locations (1)

M13 9WL

RECRUITING

Manchester Royal Eye Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Oraya Therapeutics, Inc.

INDUSTRY